MiMedx Group Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los beneficios de MiMedx Group disminuyan a un ritmo anual de 4.4%, mientras que sus ingresos anuales crecerán a un ritmo de 1% por año. Se espera que el BPA disminuya en un 4.1% al año.
Información clave
-4.4%
Tasa de crecimiento de los beneficios
-4.10%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 24.7% |
| Tasa de crecimiento de los ingresos | 1.0% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 30 Apr 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Seeking Alpha • May 09
MiMedx: The Hard Math Behind My Downgrade To Hold
Summary MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited. Management targets breakeven in Q3 via $40 million cost cuts, but execution risk remains high amid industry 'fire sale' conditions and uncertain wound care recovery. Read the full article on Seeking Alpha
Actualización del análisis • May 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price targets on MiMedx Group by several dollars to reflect lower fair value estimates, softer revenue and margin assumptions, and a higher implied future P/E, as highlighted in recent research updates from multiple firms. Analyst Commentary Recent research on MiMedx Group highlights a mixed set of views, with several firms lowering price targets while still pointing to specific factors that could support value over time.
Nuevo análisis • May 03
Surgical Adoption And Cost Cuts Will Reshape Long Term Potential For This Biologics Supplier
Catalysts About MiMedx Group MiMedx Group develops and markets placental tissue and related biologic products for wound care and surgical applications. What are the underlying business or industry changes driving this perspective?Actualización del análisis • Apr 20
MDXG: Medicare Policy Reset Will Support Chronic Wound Biologics Recovery Narrative
Analysts have trimmed the average price target for MiMedx Group from about $9.67 to $8.20, citing updated assumptions for revenue growth, profit margins, and a higher future P/E following a series of recent target cuts across the Street. Analyst Commentary Recent Street research on MiMedx Group centers on how Medicare reimbursement decisions and updated modeling are feeding into price targets, ratings, and expectations for future execution.
Nuevo análisis • Apr 18
Reimbursement And Competition Will Pressure Margins Yet Long Term Surgical Demand Will Support Upside
Catalysts About MiMedx Group MiMedx Group develops and commercializes human placental tissue and complementary products for Wound Care and Surgical applications. What are the underlying business or industry changes driving this perspective?Actualización del análisis • Apr 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Recovery Narrative
The consolidated analyst price target for MiMedx Group now reflects a modest adjustment of cents per share, as analysts weigh ongoing Medicare reimbursement changes and recent coverage initiations that highlight both prior headwinds and the potential for a rebound in chronic wound biologics. Analyst Commentary Recent research updates show a mix of optimism and caution around MiMedx Group, with views largely shaped by Medicare reimbursement shifts and how these might influence the value investors place on the chronic wound biologics portfolio.Actualización del análisis • Mar 22
MDXG: CMS Reimbursement Reset Will Set Up Biologics Comeback Narrative
Analysts have adjusted their MiMedx Group price targets, with recent moves ranging from $8 to $10 per share as they factor in shifting Medicare reimbursement developments and a potential recovery from prior headwinds. Analyst Commentary Recent research on MiMedx Group reflects a mix of optimism about potential recovery and caution around reimbursement and execution risk, which feeds directly into the range of price targets between $8 and $10 per share.Actualización del análisis • Mar 07
MDXG: Wound Care Expansion And CMS Reset Will Support Future Rebound
The analyst price target for MiMedx Group has shifted modestly to about $9.67 per share, as analysts factor in recent reimbursement headwinds that weighed on the stock, while still noting potential upside with fresh targets such as $10 from new coverage and $8 from revised models. Analyst Commentary Recent research updates around MiMedx highlight a mix of optimism about the core wound care franchise and caution around reimbursement uncertainty and valuation reset.Actualización del análisis • Feb 21
MDXG: Wound Care Portfolio Expansion Will Offset CMS Reimbursement Uncertainty
Analysts have trimmed their price targets on MiMedx Group, with one key target moving from $12 to $8, as they revisit growth, margin and P/E assumptions following recent CMS related reimbursement updates. Analyst Commentary Recent research updates point to a reset in expectations for MiMedx Group, as analysts update their models following the CMS reimbursement developments and pull back their price targets.Actualización del análisis • Feb 06
MDXG: Wound Care Portfolio Expansion Will Drive Future Upside Potential
Analysts have reduced their price target on MiMedx Group to about US$10.40 from roughly US$11.00. This change reflects slightly more cautious assumptions on fair value, revenue growth, profit margins, and future P/E multiples following recent research updates.Actualización del análisis • Jan 22
MDXG: Execution On Wound Care Expansion Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for MiMedx Group from US$12.20 to US$11.00, citing updated assumptions around discount rates, revenue growth, margins, and future P/E multiples as the key drivers behind the change. Analyst Commentary Recent Street research includes lower price targets from different firms that both bring MiMedx Group’s fair value range closer to the updated estimate.Artículo de análisis • Jan 09
Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Artículo de análisis • Nov 06
MiMedx Group's (NASDAQ:MDXG) Soft Earnings Don't Show The Whole Picture
MiMedx Group, Inc.'s ( NASDAQ:MDXG ) stock was strong despite it releasing a soft earnings report last week. We think...Artículo de análisis • Jul 04
MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Apr 17
Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Artículo de análisis • Mar 27
MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Artículo de análisis • Mar 05
Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings
The market was pleased with the recent earnings report from MiMedx Group, Inc. ( NASDAQ:MDXG ), despite the profit...Artículo de análisis • Feb 22
Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Artículo de análisis • Dec 23
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Nov 21
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Artículo de análisis • Nov 06
There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
MiMedx Group, Inc. ( NASDAQ:MDXG ) shares have had a really impressive month, gaining 27% after a shaky period...
Nuevo análisis • Sep 24
HELIOGEN's Launch And Scientific Breakthroughs Promise Growth Amid Reimbursement And Legal Challenges
The launch of HELIOGEN and strategic expansions in the surgical market underscore innovation and efforts to boost revenue through new market penetration and customer loyalty.Artículo de análisis • May 21
MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry
MiMedx Group, Inc. ( NASDAQ:MDXG ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...Artículo de análisis • May 14
We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 341 | 26 | 46 | 48 | 2 |
| 12/31/2027 | 317 | 16 | 31 | 46 | 6 |
| 12/31/2026 | 268 | -18 | -2 | 0 | 5 |
| 3/31/2026 | 389 | 31 | 69 | 71 | N/A |
| 12/31/2025 | 419 | 49 | 73 | 74 | N/A |
| 9/30/2025 | 393 | 41 | 67 | 68 | N/A |
| 6/30/2025 | 364 | 32 | 57 | 58 | N/A |
| 3/31/2025 | 352 | 40 | 64 | 66 | N/A |
| 12/31/2024 | 349 | 42 | 65 | 66 | N/A |
| 9/30/2024 | 343 | 79 | 56 | 58 | N/A |
| 6/30/2024 | 340 | 79 | 48 | 51 | N/A |
| 3/31/2024 | 335 | 68 | 34 | 37 | N/A |
| 12/31/2023 | 321 | 56 | 25 | 27 | N/A |
| 9/30/2023 | 309 | 19 | 8 | 11 | N/A |
| 6/30/2023 | 295 | 2 | -4 | -1 | N/A |
| 3/31/2023 | 281 | -18 | -15 | -12 | N/A |
| 12/31/2022 | 268 | -27 | -19 | -18 | N/A |
| 9/30/2022 | 261 | -34 | -17 | -16 | N/A |
| 6/30/2022 | 256 | -28 | -12 | -10 | N/A |
| 3/31/2022 | 258 | -19 | -7 | -6 | N/A |
| 12/31/2021 | 242 | -18 | -5 | -2 | N/A |
| 9/30/2021 | 260 | -35 | -14 | -9 | N/A |
| 6/30/2021 | 261 | -83 | -25 | -20 | N/A |
| 3/31/2021 | 246 | -88 | -30 | -25 | N/A |
| 12/31/2020 | 248 | -83 | -35 | -30 | N/A |
| 9/30/2020 | 256 | -73 | -46 | -43 | N/A |
| 6/30/2020 | 281 | -8 | -44 | -42 | N/A |
| 3/31/2020 | 294 | -17 | -39 | -36 | N/A |
| 12/31/2019 | 299 | -26 | N/A | -39 | N/A |
| 9/30/2019 | 315 | -54 | N/A | -15 | N/A |
| 6/30/2019 | 314 | -67 | N/A | -8 | N/A |
| 3/31/2019 | 342 | -48 | N/A | 10 | N/A |
| 12/31/2018 | 359 | -30 | N/A | 36 | N/A |
| 9/30/2018 | 354 | 41 | N/A | 55 | N/A |
| 6/30/2018 | 352 | 59 | N/A | 70 | N/A |
| 3/31/2018 | 333 | 65 | N/A | 62 | N/A |
| 12/31/2017 | 321 | 65 | N/A | 63 | N/A |
| 9/30/2017 | 303 | 35 | N/A | 59 | N/A |
| 6/30/2017 | 283 | 21 | N/A | 44 | N/A |
| 3/31/2017 | 264 | 15 | N/A | 37 | N/A |
| 12/31/2016 | 222 | 0 | N/A | 24 | N/A |
| 9/30/2016 | 227 | 20 | N/A | 14 | N/A |
| 6/30/2016 | 212 | 23 | N/A | 18 | N/A |
| 3/31/2016 | 200 | 27 | N/A | 14 | N/A |
| 12/31/2015 | 187 | 29 | N/A | 19 | N/A |
| 9/30/2015 | 175 | 20 | N/A | 23 | N/A |
| 6/30/2015 | 160 | 17 | N/A | 24 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de MDXG disminuyan en los próximos 3 años (-4.4% al año).
Beneficios vs. Mercado: Se prevé que los beneficios de MDXG disminuyan en los próximos 3 años (-4.4% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de MDXG disminuyan en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (1% al año) de MDXG crezcan más despacio que el mercado de US (11.5% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 1% al año) de MDXG crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MDXG se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/07 19:55 |
| Precio de las acciones al final del día | 2026/05/07 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
MiMedx Group, Inc. está cubierta por 11 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| William Plovanic | Canaccord Genuity |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |